EyeBrain Launches New Version of EyeBrain Tracker
Product News Jan 17, 2012
EyeBrain has announced that it is launching a new software version of its medical device, the EyeBrain Tracker.
This means it can now contribute to the diagnosis of this pathology by confirming eye motricity impairment, which is a sensitive marker for multiple sclerosis, as well as monitoring patients’ progress and verifying the effect of therapies prescribed by practitioners.
People with multiple sclerosis often suffer from transitory or permanent neuro-ophthalmological problems, with disruptions in eye movements affecting between 60 - 80 per cent of these patients.
The most frequently observed peculiarities are alterations in saccades and pursuits (tracking movements), as well as anomalies in patients’ ability to focus and hold a look.
These eye movement indicators are valuable for determining the state of patients suffering from multiple sclerosis and for monitoring the development of the disease.
A study carried out by Dr. E. M. Frohman, from the department of neurology at the University of Texas Southwestern, showed that oculographic techniques make it possible to detect typical eye movement anomalies in the case of multiple sclerosis more precisely than a classic visual examination carried out by a clinician.
The study, which was conducted on 279 medical practitioners, showed that, in 70 per cent of cases, a clinical examination did not enable eye movement anomalies to be detected (Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography, by Frohman TC, Frohman EM, O’Suilleabhain P, Salter A, Dewey RB Jr, Hogan N, et al).
From this standpoint, the EyeBrain Tracker can provide vital assistance to neurologists for monitoring patients suffering from multiple sclerosis.
The EyeBrain Tracker effectively makes it possible to analyze a sensitive and quantifiable marker of anatomical function, namely eye motricity, including internuclear ophthalmoplegia.
Since this marker is reproducible, it can provide quantified monitoring of the progress of the disease.
“There is currently no tool that provides an accurate quantification of the development of multiple sclerosis,” noted the chairman of EyeBrain, Serge Kinkingnéhun.
Kinkingnéhun continued, “The EyeBrain Tracker can thus be a valuable aid for neurologists in the treatment of their patients, especially regarding the choice of drugs and their dosing.”
The upgraded version of the EyeBrain Tracker medical device for application in multiple sclerosis has been available since December.
Clients who already possess the EyeBrain Tracker can upgrade it themselves with the help of the company’s after-sales service or through a maintenance visit.